CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a late-stage developer of disease-modifying therapies to treat neurodegenerative disorders, announced today continued active treatment in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback